Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of iPS cell-derived cardiomyocyte spheroids (HS-001CS) with tacrolimus in severe ischemic heart failure after CABG
jRCT2033240156Recruiting
- Sponsor
- Heartseed Inc.
- Start
- Jun 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus in ischaemic cardiomyopathy (ICM) and coronary arteriosclerosis, sponsored by Heartseed Inc. Primary endpoint: Safety. Started Jun 2024; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
ischaemic cardiomyopathy (ICM)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2033240156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240156.